Jim Cramer on Johnson & Johnson: “It’s a Textbook Slowdown Stock”

Core Viewpoint - Johnson & Johnson received FDA approval for ICOTYDE, an oral treatment for moderate to severe plaque psoriasis, which is seen as a positive development despite the stock's recent decline [1]. Group 1: Company Overview - Johnson & Johnson develops and sells healthcare products, including pharmaceuticals and medical technologies, with a focus on immunology, oncology, neuroscience, cardiovascular care, and infectious diseases [2]. Group 2: Market Reaction - Despite the positive news regarding FDA approval, the stock finished down 0.35% in a challenging market session, indicating that broader market conditions may have overshadowed the company's announcement [1]. - The current market environment is described as a "terrible, horrible, no good, very bad day," suggesting that such conditions may create buying opportunities for investors in Johnson & Johnson [1].